(Q67252039)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:620951%20AND%20SRC:MED&resulttype=core&format=json

11 September 2019

title

Phase II evaluation of VP-16-213 (NSC-141540) in patients with advanced ovarian carcinoma resistant to alkylating agents (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:620951%20AND%20SRC:MED&resulttype=core&format=json

11 September 2019

1 reference

1 reference

https://api.crossref.org/works/10.1016/0090-8258(78)90002-1

11 August 2023

author name string

J. H. Edmonson

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A620951

16 July 2022

D. G. Decker

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A620951

16 July 2022

G. D. Malkasian

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A620951

16 July 2022

M. J. Webb

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A620951

16 July 2022

E. O. Jorgensen

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A620951

16 July 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=620951

16 July 2022

publication date

1 February 1978

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:620951%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

11 September 2019

https://api.elsevier.com/content/article/PII:0090825878900021?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0090-8258(78)90002-1

https://api.elsevier.com/content/article/PII:0090825878900021?httpAccept=text/plain

11 August 2023

1 reference

https://api.crossref.org/works/10.1016/0090-8258(78)90002-1

11 August 2023

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:620951%20AND%20SRC:MED&resulttype=core&format=json

11 September 2019

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:620951%20AND%20SRC:MED&resulttype=core&format=json

11 September 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:620951%20AND%20SRC:MED&resulttype=core&format=json

11 September 2019

page(s)

7-9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:620951%20AND%20SRC:MED&resulttype=core&format=json

Second trial drugs in ovarian cancer

11 September 2019

cites work

2

1 reference

https://api.crossref.org/works/10.1016/0090-8258(78)90002-1

Evaluation of VP-16 and the combination of adriamycin and vincristine in advanced breast cancer

11 August 2023

4

1 reference

https://api.crossref.org/works/10.1016/0090-8258(78)90002-1

Phase II evaluation of VP-16-213 (NSC-141540) and cytembena (NSC-104801) in patients with advanced breast cancer

11 August 2023

5

1 reference

https://api.crossref.org/works/10.1016/0090-8258(78)90002-1

11 August 2023

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:620951%20AND%20SRC:MED&resulttype=core&format=json

11 September 2019

1 reference